ArticleJournal of personalized medicine2022
Feasibility of Adjuvant Treatment with Abemaciclib-Real-World Data from a Large German Breast Center.
Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Time Toxicity of Endocrine-based Oral CDK4/6 Inhibitor Therapies.Geburtshilfe und Frauenheilkunde · 2026Article
- Eligibility for adjuvant CDK4/6 inhibitors in HR+/HER2- early breast cancer: insights from a large cohort in central south China.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Article
- High Adherence to Adjuvant Endocrine Therapy Improves Outcome in Early Breast Cancer - Results from a Large Real-World Claims Data Analysis in Germany.Geburtshilfe und Frauenheilkunde · 2026Article
- Therapy of early breast cancer: current status and perspectives.Archives of gynecology and obstetrics · 2025Review
- Adjuvant Targeted Treatment of Early Hormone Receptor-positive HER2-negative Breast Cancer: Olaparib, Abemaciclib or Ribociclib - Which One, How and For Whom?Geburtshilfe und Frauenheilkunde · 2025Article
- Prognostic implications of risk definitions from the monarchE and NATALEE trials.Journal of the National Cancer Institute · 2025Article
- Real-World Analysis of Adherence to Abemaciclib and Endocrine Therapy in Women with HR+/HER2- Breast Cancer.Biomedicines · 2025Article
- Economic assessment of abemaciclib for the adjuvant treatment of luminal HER2- breast cancer from the perspective of the Spanish health system.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Article
- Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib.NPJ breast cancer · 2025Article
- Oral Maintenance Therapy in Early Breast Cancer-How Many Patients Are Potential Candidates?Cancers · 2025Article
- Size and Treatment Outcomes of HR+, HER2- Early Breast Cancer Population With High Risk of Recurrence: A Real-World Cohort Study With Danish Breast Cancer Cooperative Group Registry Data.Journal of health economics and outcomes research · 2025Article
- Observational
- Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability - Real-World Data from German Breast Centers.Geburtshilfe und Frauenheilkunde · 2024Article
- Feasibility of targeted therapies in the adjuvant setting of early breast cancer in men: real-world data from a population-based registry.Archives of gynecology and obstetrics · 2024Article
- Implementation and Evaluation of a Breast Cancer Disease Model Using Real-World Claims Data in Germany from 2010 to 2020.Cancers · 2024Article
- Real-world data on patients with early breast cancer who were prescribed abemaciclib adjuvant therapy in Japan.Future oncology (London, England) · 2024Observational
- The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer Centers.International journal of molecular sciences · 2023Article
- Article
- Recurrence ScoreCancers · 2022Article
- Variable Drug-Target Exposure, Tumor Signatures, and Combinatorial Targeted Treatment: Approaches of Personalized Medicine in Breast Cancer.Journal of personalized medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abemaciclib significantly improves invasive disease-free survival when combined with endocrine therapy in clinical high-risk patients with HR+/Her2- early breast cancer (eBC). The objective of the following study was to model how many patients with eBC would be available for adjuvant treatment with abemaciclib in a real-world setting. Patients that underwent complete surgical treatment for eBC between January 2018 and December 2020 in a large single-center university hospital in Germany were eligible. Descriptive statistics were used to describe the patient population that could benefit from abemaciclib according to the inclusion criteria of monarchE. Of 1474 patients with eBC, 1121 (76.1%) had a HR+/Her2- subtype. Of these, 217 (19.4%) fulfilled the monarchE inclusion criteria. Within patients that fulfilled the monarchE inclusion criteria, 48.9% received no adjuvant or neoadjuvant chemotherapy. Thus, in a real-world situation, fewer patients will be pretreated with chemotherapy than was the case in monarchE. Breast care units are facing a significant patient burden, since the 2-year abemaciclib therapy requires regular monitoring of toxicities. Specific care concepts to strengthen therapy adherence as well as further studies to deescalate adjuvant systemic treatment and individualize CDK 4/6 inhibitor therapy are therefore needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.